Wednesday, February 10, 2010, 12:23PM AEST - The Australian Stockmarket closes in 3 hours and 42 minutes.
To create a watchlist or portfolio of shares, Register

Keryx Biopharmaceuticals Inc. (KERX)

8:00AM AEST: 2.31 USD  Up 0.04 (1.76%)  
 MORE ON KERX 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Keryx Biopharmaceuticals, Inc. (NCM:KERX) Delayed quote dataEdit
Last Trade:2.31 USD
Trade Time: 8:00AM AEST
Change:Up 0.04 (1.76%)
Prev Close:2.27
Open:2.29
Bid:2.29 x 10000
Ask:3.38 x 300
1y Target Est:5.00
Day's Range:2.28 - 2.37
52wk Range:0.09 - 3.45
Volume:736,057
Avg Vol (3m):1,774,390
Market Cap:129.31M
P/E (ttm):9.75
EPS (ttm):0.24
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add KERX to Portfolio   Download Data

 HEADLINES 
A Triple in the Making
at Motley Fool (Tue 2:49AM)
Keryx Biopharmaceuticals (NASDAQ: KERX) Responds to Erroneous Report About Planned Phase III Study for Patients With Colorectal Cancer
Marketwire (Sat, Feb 6)
Biotech Stock Mailbag: Soligenix
at TheStreet.com (Fri, Feb 5)
Biopharmaceutical Stock Alert for Keryx Biopharmaceuticals Inc. Issued by InvestorSoup
GlobeNewswire (Fri, Feb 5)
Keryx, FDA agree on colon cancer drug study goals
AP (Thu, Feb 4)
Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
PR Newswire (Thu, Feb 4)
Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
PR Newswire (Wed, Feb 3)
Keryx, AEterna see positive perifosine data
AP (Sat, Jan 30)
Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia
PR Newswire (Sat, Jan 30)
Biotech Stock Mailbag: Keryx Biopharmaceuticals
at TheStreet.com (Fri, Jan 29)
More Headlines for KERX...

 ANALYST 
EPS Est (next year) (Dec-09) :0.23
EPS Est (in 2 years) (Dec-10) :-0.26
Avg Rec (current)*:1.0
PEG Ratio:0.42
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices